Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdhAQP1
- Development stage
- Phase 1
- Lead developer
- National Institute of Dental and Craniofacial Research
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intraglandular, Intraparotid, Intraductal
01
Overview
AdhAQP1 is a first-generation, E1-deleted, replication-defective serotype 5 adenoviral vector that encodes the cDNA for the water channel protein human aquaporin‑1 (hAQP1). It is designed for gene therapy by transfecting salivary gland cells to express hAQP1 in their apical and basolateral membranes. The primary indication has been the treatment of radiation-induced salivary hypofunction (xerostomia) in patients with head and neck cancer. By restoring water permeability to damaged acinar cells, it aims to increase fluid secretion from irradiated salivary glands. Clinical trials have shown increased parotid flow and improved xerostomic symptoms in some patients after a single administration, with effects lasting several weeks to years in responders. The drug was initially developed by the National Institute of Dental & Craniofacial Research (NIDCR), part of NIH[3][4][6][7][9].
- Other names
- AdhAQP1AdhAQP-1AdhAQP 1adenovirus encoding human aquaporin-1adenoviral vector encoding human aquaporin-1
02
Targets
AQP1 (Aquaporin-1)
Beyond the preview
Go deeper on AdhAQP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdhAQP1.